Cancer Immunotherapies May Deploy Nonimmune Cells Engineered to a "T"

Rather than hone the killer instincts of immune cells—and risk unleashing an overzealous horde—cancer immunotherapies may recruit and train nonimmune cells, which have the potential to be more controllable. Alternatively, cancer immunotherapies could assemble antitumor units consisting of both engineered immune cells, such as chimeric antigen receptor T (CAR-T) cells, and engineered nonimmune cells, including cells outfitted with “synthetic T-cell receptor–like signal tra